Compare IQIYI Inc - ADR (IQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Vertex Pharmaceuticals Incorporated — how do they compare? IQIYI Inc - ADR trades at $1 (market cap $979.50M), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 130.8× IQIYI Inc - ADR's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| IQ | VRTX | |
|---|---|---|
Market Cap | $979.50M | $128.16B |
Volume | 1,962,950 | 806,603 |
Sector | Media | Health |
52-Week High | $2.35 | $557.96 |
52-Week Low | $0.86 | $407.37 |
Typical Hold Time | 55 Days | 120 Days |
Enterprise Value | $2.47B | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
iQIYI (IQ) trades at $1.01, showing no change in the latest session. The stock presents a mixed picture with strong analyst support (50% buy ratings) but concerning fundamentals including negative net income margins and declining revenue. Recent earnings have consistently beaten expectations despite losses, while the company is aggressively pursuing AI-driven content production to reset its cost structure amid streaming business contraction.
The outlook remains challenging with revenue declining to $27.3 billion in 2025 and projected to fall further to $26.0 billion in 2026. While valuation metrics appear attractive with P/S of 0.25 and P/B of 0.52, persistent losses and competitive pressures in Chinese streaming markets create significant headwinds. The AI content pivot offers potential but requires successful execution to justify current analyst optimism.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
